Provided by Tiger Trade Technology Pte. Ltd.

Cytokinetics

68.26
+0.32000.47%
Post-market: 68.260.00000.00%16:10 EST
Volume:1.49M
Turnover:101.71M
Market Cap:8.35B
PE:-10.80
High:68.92
Open:67.85
Low:67.52
Close:67.94
52wk High:70.98
52wk Low:29.31
Shares:122.26M
Float Shares:119.09M
Volume Ratio:0.92
T/O Rate:1.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.3179
EPS(LYR):-5.2646
ROE:-572.15%
ROA:-24.93%
PB:-16.02
PE(LYR):-12.97

Loading ...

Earning Preview: Cytokinetics Q4 revenue is expected to increase by 296.84%, and institutional views are predominantly bullish

Earnings Agent
·
Feb 17

Cytokinetics Is Maintained at Outperform by RBC Capital

Dow Jones
·
Feb 20

RBC Raises Price Target on Cytokinetics to $101 From $95, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Feb 20

RBC Capital Sticks to Its Buy Rating for Cytokinetics (CYTK)

TIPRANKS
·
Feb 20

MYQORZO: EC Approval, Differentiated Label, and Global HCM Expansion Support Buy on CYTK

TIPRANKS
·
Feb 17

BRIEF-Cytokinetics Announces European Commission Approval Of MYQORZO

Reuters
·
Feb 17

Cytokinetics Wins European Approval for MYQORZO in HCM

TIPRANKS
·
Feb 17

EU Approves Cytokinetics' MYQORZO for Obstructive Hypertrophic Cardiomyopathy

Reuters
·
Feb 17

Cytokinetics Inc: First European Launch Expected in Germany in Q2 2026

THOMSON REUTERS
·
Feb 17

Cytokinetics Announces European Commission Approval of Myqorzo® (Aficamten) for the Treatment of Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy

THOMSON REUTERS
·
Feb 17

Cytokinetics Incorporated to Announce Fourth Quarter Results

Reuters
·
Feb 13

Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program

GlobeNewswire
·
Feb 09

EVP and Chief Commercial Officer Andrew Callos Reports Disposal of Cytokinetics Incorporated Common Shares

Reuters
·
Feb 06

Truist Raises Price Target on Cytokinetics to $92 From $84, Keeps Buy Rating

MT Newswires Live
·
Feb 03

Cytokinetics Is Maintained at Buy by Truist Securities

Dow Jones
·
Feb 03

Cytokinetics price target raised to $92 from $84 at Truist

TIPRANKS
·
Feb 03

Cytokinetics Inc : Truist Securities Raises Target Price to $92 From $84

THOMSON REUTERS
·
Feb 03

Top Cytokinetics Executive Just Cashed Out in a Notable Insider Move

TIPRANKS
·
Feb 03

Cytokinetics EVP and Chief Commercial Officer Andrew Callos Reports Disposal of Common Shares

Reuters
·
Feb 03

Cytokinetics Coverage Assumed by Barclays at Overweight

Dow Jones
·
Jan 28